Translation for cancer therapeutics is taking too long and costing too much, according to Dr. Philip Schein, visiting professor in cancer pharmacology at the University of Oxford in England and leading international authority in the treatment of cancer. How can we improve in the future? Join host Dr. Bruce Bloom's conversation with Dr. Schein and Scott Riccio, founder and director for Accelerate Progress, a not-for-profit "action-tank" focused on bringing new promising and potentially lifesaving therapies to cancer patients, about why and how we should truncate the lengthy approval process and decrease the costs of bringing new therapeutics to market.
